About Dr. B. J. Srinivasa
Dr. B. J. Srinivasa is a highly accomplished and leading medical oncologist in Bengaluru, with over 25 years of extensive experience in comprehensive cancer management. He is renowned for his expertise in the systemic management of a wide array of cancers, including breast cancer, GI cancer, lymphoma, myeloma, lung cancer, and head and neck cancer. Dr. Srinivasa is proficient in administering advanced systemic treatments such as chemotherapy, immunotherapy, targeted therapy, and hormone therapy. With a strong interest in clinical research and tumour genetics, he champions precision oncology, tailoring genomic-based treatment strategies to each patient’s unique health needs. His exceptional academic record, highlighted by a gold medal in DNB Medical Oncology, underscores his commitment to advancing cancer care.
Qualifications & Credentials
- MBBS - Bachelor of Medicine and Bachelor of Surgery
- MD (General Medicine) - Doctor of Medicine
- DNB (Medical Oncology) - Diplomate of National Board in Medical Oncology
- Recipient of the 'President NBE Gold Medal' with certification by the National Board of Examination, New Delhi.
- Member: Bangalore Oncology Group.
- Primary investigator and co-investigator for numerous clinical trials.
Areas of Expertise
- Breast Cancer
- GI Cancer
- Lymphoma
- Myeloma
- Lung Cancer (Non-Small Cell Lung Cancer - NSCLC)
- Head and Neck Cancer
- Prostate Cancer
- Sarcomas
- Ovarian Cancer (Epithelial)
- Systemic Cancer Treatments
- Precision Oncology (Genomic-based cancer treatment)
- Clinical Research
- Tumour Genetics
- Cancer Screening (Preventive Oncology)
- Administration of advanced chemotherapy regimens (including metronomic chemotherapy, Eribulin mesylate, Pemetrexed, Carboplatin, Gemcitabine).
- Immunotherapy (e.g., Nivolumab, Pembrolizumab for recurrent SCC).
- Targeted Therapy (e.g., Afatinib for EGFRm+ NSCLC, Regorafenib for mCRC, Pazopanib).
- Hormone Therapy for Breast Cancer & Prostate Cancer.
- Intraperitoneal Chemotherapy for refractory ovarian cancer.
- Allogenic Haematopoietic Stem Cell Transplant (for AML M2).
Professional Experience
- Current Affiliations:
- Senior Medical Oncologist, HCG Cancer Centre - Double Road, Bengaluru
- Senior Medical Oncologist, HCG Cancer Centre - K.R. Road, Bengaluru
- Past Affiliations:
- Consultant, Manipal Tumkur Hospital, Tumkur
- Consultant, Father Muller Medical College, Mangalore
- Consultant, Vaatsalya Hospital, Shivamogga
- Primary investigator and co-investigator for clinical trials on various cancer types, new chemotherapy drugs, and new immunotherapy drugs.
- Authored numerous publications in prestigious national and international peer-reviewed medical journals.
- Active advocate for cancer awareness programmes.
- Recipient of the 'President NBE Gold Medal' for securing the highest marks in the medical oncology examination.
- Pioneered medical oncology treatments with a special interest in precision care through genomic-based cancer treatment.
- Extensive research contributions, including Indian subset analyses for drugs like Afatinib and studies on metronomic chemotherapy and predictive biomarkers.
- Published widely on diverse oncology topics, from rare case reports to efficacy studies of advanced therapies.
Awards & Recognitions
- 'President NBE Gold Medal' - National Board of Examination, New Delhi (for highest marks in medical oncology examination).
- Recognised for extensive contributions to clinical research and numerous publications in reputable medical journals.
- Active advocate of cancer awareness programmes.
Research & Publications
- "Tumor to tumor metastasis of renal cell carcinoma in carcinoma stomach: An unusual case presentation" Article (Sep 2024)
- "The role of p53 and ki67 in predicting clinical outcome in breast cancer patients" Article (Mar 2023)
- "Recurrent squamous cell carcinoma of the skin treated with immunotherapy" Article (Dec 2022)
- "484P Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials" Article (Nov 2019)
- "503P Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials" Article (Nov 2019)
- "P2.01-99 A Phase IIIb Open-Label Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis" Article (Oct 2019)
- "P1.14-62 Afatinib in EGFR TKI-Naïve Patients with EGFR Mutation-Positive NSCLC: Combined Analysis of Two Single-Arm Phase IIIb Studies" Article (Oct 2019)
- "Combined DPD and UGT1A1 Mutation in a Single Patient: A Case Report" Article (Jan 2017)
- "Prospective Analysis of Patients Treated with Chemotherapy in Metastatic Adenocarcinoma of Lung—Single Centre Experience" Article (Jan 2017)
- "KDR gene as a Predictive Biomarker of Response to Regorafenib in Patients with Metastatic Colorectal Cancer (mCRC)" Article (Jan 2017)
- "Case Report Breast Metastasis from Adenocarcinoma of Lung: A Case Report" Article (Dec 2016)
- "Primary Rhabdomyosarcoma of Breast" Article (May 2013)
- "Adenocarcinoma Colon Masquerading as Acute Leukemia." Journal of Case Reports (2012)
- "Case of fosphenytoin-induced acute cerebellar dysfunction and pituitary bleeding causing central diabetes insipidus in a case of AML M2 during allogenic hematopoietic stem cell transplant." Int J Pharmacol and Clin Sci (2012)
- "Sepsis Mimicking TTP-Case Report and Review of Literature." Journal of Surgery & Anesthesia Research (2020)
- "The fundamentals to minimize the culture failure in hematological malignancies." OALib (2020)
- "Clinical Profile of Carcinoma Breast Patients Treated with Trastuzumab: A Single Centre Study." Advances in Breast Cancer Research (2020)
- "Indian subset analysis of a phase IIIb open-label study of afatinib in epidermal growth factor receptor tyrosine kinase inhibitor-naïve patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer." Oncol J India (2021)
- "Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies." Front Oncol (2021)
- Has served as a primary investigator and co-investigator for numerous clinical trials on various types of cancer and novel chemotherapy/immunotherapy drugs.
Patient Success Stories & Testimonials
- Successfully managed numerous cases of breast cancer, GI cancer, lung cancer, and lymphoma through personalised systemic treatment strategies.
- Pioneered precision oncology by incorporating genomic-based cancer treatment for enhanced patient outcomes.
- Instrumental in clinical trials, bringing new chemotherapy and immunotherapy drugs to patients.
- Provided effective treatment for rare and complex cases, as evidenced by his extensive publications on unique case reports.
- "Dr. Srinivasa is an outstanding medical oncologist and truly a top cancer specialist in Bengaluru. His detailed approach to my lung cancer treatment, incorporating targeted therapy, made a significant difference. I felt genuinely cared for and confident in his expertise." - Mrs. Lakshmi D.
- "My family and I are incredibly grateful to Dr. B. J. Srinivasa for his exceptional care during my wife's breast cancer journey. His focus on precision oncology and personalised treatment was key to her successful recovery." - Mr. Anand Rao
- "When faced with a lymphoma diagnosis, we sought out the best, and Dr. Srinivasa delivered. His deep knowledge and compassionate support were invaluable. He's not just a doctor but a true advocate for his patients." - The Prakash Family
Treatment Approach & Philosophy
- Patient-Centred Care: Dr. B. J. Srinivasa is deeply committed to delivering patient-focused care. His philosophy revolves around understanding each patient's specific health needs and providing personalised treatment strategies. He prioritises effective communication and ensuring that patients are well-informed about their genomic-based cancer treatment options. He also actively advocates for cancer awareness, believing in empowering patients through knowledge.
- Technology & Innovation: With a keen interest in clinical research and tumour genetics, Dr. Srinivasa is at the forefront of precision oncology. He leverages advanced systemic therapies, including state-of-the-art immunotherapy, targeted therapy, and novel chemotherapy drugs, striving to make cancer medicine more precise, effective, and safe. His extensive publication record demonstrates his dedication to integrating the latest scientific advancements into clinical practice.
Treatment Costs
| Treatment Procedure | Estimated Cost (INR) | Estimated Cost (USD) |
| Breast Cancer Chemotherapy/Targeted Therapy | 3,00,000 - 12,00,000 | 3,600 - 14,500 |
| GI Cancer Systemic Therapy (Chemo/Targeted) | 4,00,000 - 15,00,000 | 4,800 - 18,000 |
| Lung Cancer Immunotherapy/Targeted Therapy | 8,00,000 - 28,00,000 | 9,600 - 34,000 |
| Lymphoma/Myeloma Chemotherapy | 3,50,000 - 12,00,000 | 4,200 - 14,500 |
| Head and Neck Cancer Systemic Therapy | 2,80,000 - 10,00,000 | 3,400 - 12,000 |
| Prostate Cancer Hormone Therapy | 1,50,000 - 6,00,000 | 1,800 - 7,200 |
International Patient Assistance
- Language Support: The Cancer Rounds team offers comprehensive language support for international patients, ensuring seamless communication and understanding throughout their cancer treatment journey in India.
- Visa & Travel Assistance: The Cancer Rounds team provides dedicated assistance with visa applications, travel arrangements, airport transfers, and arranging suitable accommodation options for international patients and their accompanying family members.
- Pre-treatment Virtual Consultations: International patients can easily arrange pre-treatment virtual consultations with Dr. B. J. Srinivasa for initial discussions, expert medical record review, and to receive second opinions before travelling to India.









